Taicang's Connect Biopharma Files for $100 Million NASDAQ IPO

Connect Biopharma of Taicang has filed for a NASDAQ IPO that could raise $100 million to support its clinical-stage portfolio of therapies for T cell-driven inflammatory diseases. Connect's lead candidate, CBP-201, is an antibody that targets interleukin-4 receptor alpha for inflammatory diseases such as atopic dermatitis and asthma. The company expects to report data from a Phase IIb trial in the 2H21. Connect says it uses functional cellular assays to conduct primary drug screens instead of high-throughput biochemical assays, resulting in differentiated products. More details.... Share this with colleagues: // //